Starting doses are often in the 2.5 mg range, with incremental increases toward therapeutic targets of 1015 mg per week
This unique mechanism sets it apart from single-action medications like semaglutide
FSSAI certified, NABL tested
In hepatocytes, ATGL undergoes S-acylation by the protein acyltransferase identified as ZDHHC11
Safety and monitoring considerations for research applications include assessment of potential effects on tissue regeneration, immune function, and wound healing capacity, as senescent cells may play beneficial roles in some biological processes
Similarly, a 2023 review published in Frontiers in Immunology found that GLP-1 receptor agonists reduced pro-inflammatory cytokines and oxidative stress markers across multiple tissues